FDA Approves Reduced Clozapine Monitoring; Increased Patient Access Versus Increased Risk

摘要

Reducing the mandatory weekly monitoring of white blood cell (WBC) count during clozapine (Clozaril) treatment to a biweekly schedule after six months of treatment could result in twice the incidence of agranulocytosis and one death annually from blood dyscrasia in the approximately 67,000 patients using clozapine, according to testimony by Clozaril manufacturer, Novartis.